Chattem Q2
This article was originally published in The Rose Sheet
Executive Summary
Selsun Blue, Gold Bond and Icy Hot contribute to 10% increase in revenues in the fiscal second quarter to $70.1 mil. including royalties, the firm reports June 18. Sales of Selsun Blue jumped 12% in the quarter over the year ago period due to a strong marketing campaign and initial shipments of a new conditioner, while net sales of Gold Bond grew 32%, led by a double-digit increase from the lotion, cream and foot segments, Chattem says. Strong results of some brands were offset by a 55% year-over-year decline in sales of Dexatrim diet pills. Operating income excluding settlement charges related to Dexatrim litigation rose 16% to $19.8 mil., while net income excluding settlement charges and charges related to debt extinguishment soared 41% to $10.6 mil...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.